By combining PTT, IDO inhibition, and PD-L1 blockade, the growth of irradiated tumor in distant sites without PTT treatment can be effectively inhibited by targeting multiple antitumor immune pathways to induce synergistic antitumor immunity [132]. The gene discussed is IDO1; the disease is neoplasm.